Tokyo Medical University Hospital ( Site 2467)

Shinjuku, Tokyo 160-0023

1 studies enrolling now · 1 studies all time

What they study most

Breast Neoplasms

Studies at this site

• A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) — Recruiting now